Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults[1].
[1]. Dhillon S. Eptinezumab: First Approval.Drugs. 2020;80(7):733-739.
















